Cryoport, Inc. (NASDAQ:CYRX) Receives $64.33 Consensus Price Target from Brokerages

Shares of Cryoport, Inc. (NASDAQ:CYRX – Get Rating) have been given an average recommendation of “Buy” by the eight ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and two have given a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $61.83.

Several analysts have recently weighed in on CYRX shares. TheStreet lowered Cryoport from a “c-” rating to a “d+” rating in a report on Friday, January 28th. Roth Capital cut their price objective on Cryoport from $90.00 to $67.00 in a report on Tuesday, May 3rd. BTIG Research cut their price objective on Cryoport from $95.00 to $60.00 in a report on Friday, May 6th. B. Riley cut their price objective on Cryoport from $61.00 to $55.00 in a report on Tuesday. Finally, Zacks Investment Research upgraded Cryoport from a “strong sell” rating to a “hold” rating in a report on Wednesday, May 4th.

Shares of CYRX stock opened at $23.69 on Friday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 14.48 and a current ratio of 14.98. Cryoport has a 1 year low of $19.82 and a 1 year high of $86.30. The stock has a fifty day moving average of $29.07 and a two-hundred day moving average of $44.97. The firm has a market capitalization of $1.17 billion, a PE ratio of -3.88 and a beta of 1.30.

Cryoport (NASDAQ:CYRX – Get Rating) last announced its quarterly earnings results on Thursday, May 5th. The consumer goods maker reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.13). Cryoport had a negative return on equity of 13.79% and a negative net margin of 128.78%. The business had revenue of $52.30 million for the quarter, compared to analyst estimates of $52.86 million. During the same quarter last year, the firm posted ($0.13) EPS. The company’s revenue was down 1.9% compared to the same quarter last year. Equities research analysts predict that Cryoport will post -0.63 earnings per share for the current fiscal year.

In related news, insider Mark W. Sawicki sold 1,410 shares of the company’s stock in a transaction on Wednesday, March 9th. The stock was sold at an average price of $31.05, for a total transaction of $43,780.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Robert Stefanovich sold 1,095 shares of the company’s stock in a transaction on Wednesday, March 9th. The shares were sold at an average price of $31.05, for a total value of $33,999.75. The disclosure for this sale can be found here. Insiders have sold 5,803 shares of company stock worth $180,183 over the last ninety days. 9.70% of the stock is owned by insiders.

A number of large investors have recently bought and sold shares of the stock. State Street Corp raised its position in Cryoport by 14.3% during the first quarter. State Street Corp now owns 1,058,900 shares of the consumer goods maker’s stock valued at $36,966,000 after buying an additional 132,231 shares during the period. Graham Capital Management L.P. acquired a new position in Cryoport during the first quarter valued at $537,000. Invesco Ltd. raised its position in Cryoport by 17.7% during the first quarter. Invesco Ltd. now owns 3,228,313 shares of the consumer goods maker’s stock valued at $112,700,000 after buying an additional 485,972 shares during the period. UBS Group AG raised its position in Cryoport by 160.2% during the first quarter. UBS Group AG now owns 211,140 shares of the consumer goods maker’s stock valued at $7,371,000 after buying an additional 130,000 shares during the period. Finally, Renaissance Technologies LLC raised its position in Cryoport by 1,965.0% during the first quarter. Renaissance Technologies LLC now owns 466,700 shares of the consumer goods maker’s stock valued at $16,292,000 after buying an additional 444,100 shares during the period.

Cryoport Company Profile (Get Rating)

Cryoport, Inc, a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle.

Recommended Stories